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Abstract
After the successful introduction of highly active antiretroviral 
agents the survival of patients infected with the human 
immunodeficiency virus (HIV) in developed countries has 
increased substantially. This has allowed the surfacing 
of several chronic diseases among which cardiovascular 
disease (CVD) is prominent. The pathogenesis of CVD in 
HIV is complex and involves a combination of traditional and 
HIV related factors. An accurate assessment of risk of CVD 
in these patients is still elusive and as a consequence the 
most appropriate preventive and therapeutic interventions 
remain controversial. 
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Core tip: Infection with the human immunodeficiency 
virus (HIV) was initially universally lethal but with the 
introduction of highly active antiretroviral therapies 
(HAART) the life span of HIV infected patients has 
drastically increased. Along with the lengthening of life 
span chronic diseases such as non-acquired immuno-
deficiency syndrome related cancers and cardiovascular 
diseases surfaced. Currently cardiovascular disease is 
the primary cause of death among HIV infected patients 
in industrialized countries and its pathogenesis is very 
complex. A combination of direct virion injury, chronic 
low-grade inflammation, adverse cardiometabolic effects 
of HAART and high burden of traditional risk factors 
REVIEW
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4330/wjc.v7.i10.633
633 October 26, 2015|Volume 7|Issue 10|WJC|www.wjgnet.com
World J Cardiol 2015 October 26; 7(10): 633-644
ISSN 1949-8462 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
World Journal of 
CardiologyW J C
contribute to this new epidemic. 
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INTRODUCTION
In the era of highly active antiretroviral therapy (HAART), 
the prognosis for human immunodeficiency positive 
(HIV+) patients in developed countries has dramatically 
improved[1,2]. As a consequence HIV infected patients 
live longer[3] and the medical care for this population is 
becoming more focused on the management of non- 
acquired immunodeficiency syndrome (AIDS) related 
morbidities, including cardiovascular diseases (CVDs)[4].
Although CVD is a leading cause of mortality and 
morbidity in HIV+ patients[5,6], there remains some 
controversy as to whether the disease is accelerated 
(promoted by traditional and non-traditional risk 
factors for atherosclerosis) or accentuated (greater 
prevalence of traditional cardiovascular risk factors) 
in these patients[7,8]. The prevention and treatment 
may vary considerably according to which mechanism 
is the prevailing one. In this review, we address the 
epidemiology of CVD in HIV+ patients, we discuss the 
impact of traditional and HIV-related risk factors; we 
review risk assessment for CVD in HIV and provide 
a brief overview of future therapeutic approaches to 
prevention of CVD in patients infected with HIV.
BURDEN OF CVD IN HIV
Epidemiology of CVD in HIV (Table 1)
A large body of evidence supports the notion that 
the burden of both clinical and sub-clinical CVD is 
increased in HIV infected patients. Investigators in the 
Veterans Aging Cohort Study Virtual Cohort (VACS-VC) 
analyzed data collected in 82459 veterans followed for 
an average of 5.9 years. The 27350 veterans infected 
with HIV had a significantly higher risk of myocardial 
infarction (AMI) compared with uninfected veterans 
(HR, 1.48; 95%CI: 1.27-1.72)[6]. The highest AMI risk 
was recorded among patients with HIV-RNA levels of 
at least 500 copies/mL and CD4 cell (CD4+) count 
less than 200 cell/mL; the risk remained elevated 
among patients who achieved HIV-RNA levels less 
than 500 copies/mL over time, suggesting that HAART 
may have contributed to some of the AMI risk[6]. The 
increased risk of CVD was noted both in HIV infected 
men and women[9]. When the VACS-VC participants 
were categorized according to the presence or absence 
of standard risk factors (diabetes mellitus, current 
smoking, total cholesterol, blood pressure, statins 
and antihypertensive medications use), HIV-infected 
veterans without major CVD risk factors had a 2-fold 
greater risk of AMI compared with uninfected veterans 
and the risk increased rapidly with each additional 
risk factor added[10]. In a cohort of 3851 HIV-infected 
patients examined at two Boston health care facilities 
the rate of AMI was significantly higher than in 
1044589 controls after adjustment for age, sex, race, 
hypertension, and dyslipidemia (RR, 1.75; 95%CI: 
1.51-2.02; P < 0.0001). Importantly, race appeared 
to have a different influence on the rate of AMI, with 
risk being higher in African-Americans and in Hispanics 
compared to Caucasians[11]. Although the prevalence of 
hypertension, diabetes mellitus and dyslipidemia was 
higher in HIV patients, this study further suggested 
that traditional risk factors cannot fully account for 
the increased risk of CVD in HIV[11]. Other studies 
performed outside of the US confirmed an increased 
risk of CVD in infected individuals[12,13].
The evidence of an increased risk of CVD in HIV 
extends to studies of subclinical atherosclerosis. 
Hsue et al[14] measured carotid artery intima-media 
thickness (IMT), an independent predictor of AMI 
and stroke[15,16], in 148 HIV+ patients and 63 age 
and sex matched controls. They reported that the 
mean carotid IMT of HIV+ patients was significantly 
greater and progressed faster in HIV+ patients than 
in controls. Of note, HIV infection was a predictor of 
carotid IMT independent of all other risk factors such 
as age, sex, smoking, HTN, lipid abnormalities and 
diabetes mellitus; a nadir CD4 count < 200 cells/mL 
was associated with IMT progression. However, Currier 
et al[17] failed to show any association between HIV 
infection and rate of carotid IMT progression. 
Coronary computed tomography with and without 
intravascular iodinated contrast provides information 
about coronary artery calcium and non-calcified 
plaques both measures of subclinical atherosclerosis. 
Post et al[18] showed that HIV-infected men had a 
greater prevalence of coronary artery plaques compared 
to uninfected men and more extensive non-calcified 
plaques. On the contrary, the extent of coronary 
calcification was similar in the two groups. 
In contrast with the above reported increased 
prevalence of CVD, Klein et al[19] recently reported a 
decline in incidence of AMI and CVD in HIV-patients. 
They reviewed data collected among the members of 
Kaiser Permanente Southern California and Northern 
California health plans between 1996 and 2011 
(24768 HIV-infected patients and 257600 controls). 
The unadjusted relative risk of AMI for HIV+ patients 
decreased from 2.0 in 1996-1999 to 1.2 in 2010-2011, 
and the adjusted RR declined from 1.8 in 1996-1999 
to 1.0 in 2010-2011 (Table 2). The decreased incidence 
of AMI in HIV+ patients may be due to the use 
of more lipid-friendly HAART medications, earlier 
initiation of HAART, resulting in lower incidence of severe 
immunodeficiency, and better control of CVD risk factors. 
The latter notion was supported by the finding that the 
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Framingham risk scores were lower in HIV+ patients in 
more recent years compared to the late 90’s[19].
In summary, a considerable body of literature 
shows a greater incidence of clinical CVD and a 
greater prevalence of subclinical atherosclerosis in HIV 
infected patients compared to the general population, 
supporting the notion that HIV is an independent risk 
factor for CVD. Whether the recently reported trend 
reversal is due to a greater awareness and more 
effective implementation of preventive measures in 
HIV+ patients remains to be demonstrated in different 
geographical areas and health delivery settings.
Etiopathogenesis of atherosclerosis in HIV 
Infection related factors: The increased CVD risk 
in HIV may be dependent on a direct role of the HIV 
virus and on the immunological dysregulations caused 
by chronic HIV infection (Figures 1 and 2); data from 
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observational studies provide evidence that both of 
these elements are involved[6,10,11]. 
The importance of continuous suppression of viral 
replication was investigated in the strategies for 
management of antiretroviral therapy (SMART) study[20]. 
The investigators compared the risk of all-cause death 
and cardiovascular, renal or hepatic complications in 
2720 HIV+ patients receiving intermittent antiretroviral 
therapy and 2752 HIV+ patients receiving continuous 
antiretroviral therapy[20]. After a mean follow-up of 
16 mo, the risk of death from any cause and for major 
cardiovascular, renal and hepatic diseases was 
significantly higher in patients who received intermittent 
compared to those who received continuous anti-
retroviral therapy (HR for all-cause death: 2.6; 95%CI: 
1.9-3.7; P < 0.001, HR for major CVD, renal and 
hepatic disease: 1.7; 95%CI: 1.1-2.5; P = 0.009). The 
authors suggested that the increased CV risk may be 
Table 1  Epidemiological studies evaluating the impact of human immunodeficiency virus on cardiovascular disease
Ref. Size Follow-up Findings
Freiberg et al[6] 82459
27350 HIV+
55109 HIV- 
5.9 yr Increased risk of MI among HIV+ patients
VACS-VS study[6] (HR: 1.48; 95%CI: 1.27-1.72)
Womack et al[9]
VACS-VS study
2187 women
32% HIV+ 
6 yr Increased risk of CVD in HIV+ women compared to uninfected women (HR: 2.8; 95%CI: 1.7-4.6)
Paisible et al[10]
VACS-VS study  
81322 33% HIV+ 5.9 yr HIV+ veterans without major CVD risk factors had a 2-fold increased risk of MI compared with
HIV- veterans without CVD risk factors (HR: 2.0; 95%CI: 1.0- 3.9)
Triant et al[11] 3851 HIV+ 1044589 
HIV-
8 yr Increased risk of MI among HIV+ patients (RR: 1.75; P < 0.0001)
Silverberg et al[12] 22081 HIV+
23069 HIV- 
13 yr Higher risk of MI among HIV+ patients with a low recent or nadir CD4 cells (< 200) compared 
with HIV- subjects 
(RR, 1.76; 95%CI: 1.31-2.37 for low recent CD4
RR, 1.74; 95%CI: 1.47-2.06 for low nadir CD4)
Lang et al[13]
FHDH-ANRS CO4
74958 HIV+ 6 yr The risk of MI was higher in both HIV+ men and women compared with the general population
Standardized mortality ratio: 1.4 (95%CI: 1.3-1.6) for HIV+ men and 2.7 (95%CI: 1.8 -3.9) for 
HIV+ women compared with the general population 
Hsue et al[14] 148 HIV+
63 HIV-
1 yr Higher baseline carotid IMT of HIV+ patients (P = 0.0001) and faster progression (P = 0.002)
Currier et al[17] 133 subjects in 45 
triads1 
144 wk HIV infection and PI use did not contribute to the rate of carotid IMT progression. The median 
paired difference in IMT change between the PI and non-PI subjects was not statistically 
significant (P = 0.19). When the HIV+ groups were combined and compared with the HIV-
negative group, the difference in progression was also not significant (P = 0.71)
Post et al[18] 618HIV+
383HIV- men 
cross-sectional 
study 
HIV-infected men had a greater prevalence of CAC [PR: 1.21 (95%CI: 1.08); P = 0.001] and any 
plaque [PR: 1.14 (CI: 1.05- 1.24); P = 0.001], including non-calcified [PR: 1.28 (CI: 1.13-1.45); P < 
0.001) and mixed [PR: 1.35 (CI: 1.10-1.65); P = 0.004) plaque, than uninfected men
Klein et al[19] 
VACS-VS study 
95687
31% HIV+ 
15 yr Decline in adjusted MI rate ratio for HIV status over time, reaching 1 (95%CI: 7-1.4) in 2010-2011
1Each triad consisted of one subject from each of the following categories: (1) HIV+ with continuous PI therapy; (2) HIV+ without prior PI use; (3) HIV- 
subject. HIV: Human immunodeficiency virus; IMT: Intima-media thickness; MI: Myocardial infarction; PR: Prevalence ratio; CVD: Cardiovascular disease.
Table 2  Crude and adjusted rate ratios (95%CI) of myocardial infarction comparing human immunodeficiency virus infected and 
uninfected patients during a 13-year time span in the California Kaiser Permanente health system
Year 1996-2011 1996-1999 2000-2003 2004-2007 2008-2009 2010-2011
Crude 1.6 (1.5, 1.8) 2.0 (1.5, 2.8) 2.0(1.6, 2.5) 1.5 (1.2, 1.9) 1.5 (1.1-2.0) 1.2 (0.9-1.6)
Adjusted 1.4 (1.2, 1.6) 1.8 (1.3, 2.6) 1.7(1.4, 2.1) 1.3 (1.0, 1.6) 1.3 (0.9, 1.7) 1.0 (0.7, 1.4)
Modified from Klein et al[19].
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Some investigators reported a direct association[21,22], 
while others were not able to identify one[24-26]; therefore 
this aspect of the CV pathogenicity of HIV needs to be 
clarified further.
The HIV can penetrate into endothelial cells 
utilizing CD4 receptors, galactosyl-ceramide receptors 
or chemokine receptors pathway[27-29], and different 
components of the HIV may have a role in the patho-
genesis of CVD. Gp120 is a glycoprotein exposed 
on the surface of the HIV envelope and can also be 
found in the circulation from viral turn over[30,31]. It 
mediates HIV-1 entry into human cells by interacting 
with the HIV receptor for CD4 and co-receptors CXCR4 
or CCR5[32]. Jiang et al[33] showed that Gp120 and 
tumor necrosis-alpha (TNF-α) synergistically decrease 
endothelial nitric oxide synthase (eNOS) and nitric 
oxide (NO) levels in both porcine and human coronary 
artery endothelial cells. NO is an important factor in 
the regulation of vascular tone and inhibition of platelet 
adhesion and aggregation[34]. HIV infection is a chronic 
inflammatory state, characterized by elevated serum 
levels of factors such as TNF-α and TNF-b, interferon 
gamma (IFN-g) and monocyte chemo-attractant 
protein-1 (MCP-1)[32,35,36] and Gp120 can magnify the 
pro-atherosclerotic effects of these mediators. Gp120 
can also induce apoptosis by interacting with CXCR4, 
the consequence of alternating low and high CD4 cell 
numbers and viral loads experienced by the patients 
while receiving intermittent antiretroviral therapy, hence 
the importance of early and vigorous control of HIV 
replication and immune dysfunction[20].
In a cohort study of 22081 HIV+ and 230069 HIV-
adult patients Silverberg et al[12] showed that the risk 
of AMI was 44% higher in HIV+ subjects compared 
with HIV- controls after adjustment for traditional risk 
factors. HIV+ patients with a nadir CD4 cell count 
< 200/mcl had a greater risk of AMI compared to 
controls[12]. However, the AMI rate of HIV+ subjects 
with a recent or nadir CD4 cell count ≥ 500 /mcl and 
that of HIV- subjects was the same. In a case-control 
study of 289 HIV+ patients and 884 HIV-infected 
controls[21], a viral RNA level > 50 copies/mL, a low 
CD4 nadir and a high current CD8 count (> 1150/
mm3) were significantly associated with an increased 
risk of AMI. The ratio of nadir CD4/current CD8 count 
was the best predictor of an event[21]. 
In summary it would appear that a tight control of 
the HIV reproduction and maintenance of a good CD4 
count may be protective against the risk of CV events. 
However, there exists conflicting evidence as to the 
actual association between CD4 cell count and the risk 
of AMI[22,23], as well as the HIV RNA levels and CV risk. 
HIV Gp120, Tat and Nef
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Figure 1  Putative mechanisms by which the human 
immunodeficiency virus virion increases the risk 
of atherosclerosis. The virus induces expression of 
adhesion molecules for leukocytes, reduce the secretion 
of nitric oxide with reduced vasodilation and induce 
endothelial cells apoptosis. ICAM: Intercellular adhesion 
molecule; VCAM: Vascular cell adhesion molecule; eNOS: 
Endothelial nitric oxide synthase; NO: Nitric oxide; HIV: 
Human immunodeficiency virus. 
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Figure 2  The human immunodeficiency virus promotes 
a state of low-grade chronic inflammation that increases 
the risk of atherosclerosis through the activation of 
lymphocytes, monocytes and macrophages. HIV: Human 
immunodeficiency virus; HLA: Human leukocyte antigen. 
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markers, such as soluble CD163, CD14 and MCP-1 
have been associated with subclinical coronary artery 
atherosclerosis, after adjustment for traditional CVD 
risk factors, in a large cohort of HIV-infected men[58]. 
T-lymphocytes are also activated in HIV infection[59]. 
In the Women Interagency HIV study, Kaplan et 
al[59] showed that HIV infection was associated with 
significantly elevated levels of activated [CD38+ human 
leukocyte antigen (HLA)-DR+] peripheral CD4+ and CD8+ 
cells and CD8+ senescent cells (CD28-CD57+). The trend 
was reduced but not totally reversed after effective viral 
suppression with HAART. After adjustment for multiple 
confounders, CD4+ and CD8+ cell activation and CD8+ 
senescent cells were associated with subclinical carotid 
artery lesions detected by 2D ultrasound[59]. 
Traditional risk factors in HIV: Traditional risk 
factors are more prevalent in HIV infected patients and 
likely represent a major driver for CVD in HIV. 
(1) Cigarette smoking: The prevalence of cigarette 
smoking in HIV infected patients has been reported 
to be higher than in the general population. Analyzing 
data from 4217 infected (who participated in the 
Medical Monitoring Project) and 27731 non infected 
adults (who participated in the National Health 
Interview Survey in 2009), Mdodo et al[60] reported 
that 42.4% of HIV patients (95%CI: 39.7%-45.1%) 
were current cigarette smokers, while 20.3% (CI: 
18.6%-22.1%) were former smokers, and 37.3% 
(CI: 34.9%-39.6%) had never smoked. Compared 
with the US adult population, in which an estimated 
20.6% of adults smoked cigarettes in 2009, adults 
with HIV were nearly twice as likely to smoke [adjusted 
prevalence difference, 17.0% (CI: 14.0%-20.1%)], 
but were less likely to quit smoking (quit ratio, 32.4% 
vs 51.7%). A higher prevalence of smoking was also 
described in the SMART trial[61] and in the D:A:D 
study[62], where the rates of smoking were 40.5% and 
51.5% respectively in HIV infected patients. Social 
and psychological factors such as ethnicity, lower 
educational level, poverty, illicit drug use, depression 
are likely contributing to the tobacco epidemic in 
HIV[60]. The noxious effects of smoking may be enhanced 
in HIV patients. Recently Helleberg et al[63] reported 
a greater number of life-years lost due to smoking in 
HIV infected patients compared to smoking controls 
[12.3 years (95%CI: 11.5-13.0) vs 3.6 years (95%CI: 
3.1-4.0), respectively].
(2) Diabetes mellitus: Using data from the Multicenter 
AIDS Cohort Study (MACS), Brown et al[64] reported 
that the incidence of diabetes mellitus in HIV-infected 
men with HAART exposure was four fold higher than 
that of HIV-seronegative men. Subsequently De Wit et 
al[65] reported an incidence rate of 5.72 per 1000 patient 
follow-up year (95%CI: 5.31-6.13). The incidence of 
diabetes increased with cumulative exposure to HAART, 
and the association remained significant after adjustment 
for confounding factors. Besides the possible influence of 
HAART, some investigators reported a higher incidence 
a chemokine receptor[37,38], which is also expressed on 
vascular endothelium[39,40].
The trans-activator of transcription (Tat) protein is a 
regulatory protein that enhances the efficiency of viral 
transcription[41]. In a study on the role of Tat on the 
expression of adhesion molecules in human endothelial 
cells, Tat was shown to induce the expression of 
intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1), and E-selectin[42]. In 
the early phases of atherosclerosis, leukocytes adhere 
on the surface of endothelial cells and subsequently 
transmigrate between vascular endothelial cells into 
the intima layer of the vessel wall. While E-selectin 
is involved in the initial rolling of leukocytes on the 
endothelial cells[40], ICAM-1 and VCAM-1 induce firm 
adhesion and transmigration of leukocytes across the 
vascular endothelium[43]. High levels of soluble ICAM-1, 
VCAM-1 and E-selectin are associated with and 
increased risk of AMI in healthy men and women[44-46]. 
The levels of ICAM-1, VCAM-1 and E-selectin are 
elevated in HIV+ patients and there is a correlation 
between ICAM-1 concentration and the progression of 
HIV disease as well as the reduction of CD4 count[47,48]. 
Similarly to Gp120, Tat can also decrease endothelium 
dependent vasorelaxation and eNOS secretion in 
porcine coronary arteries[49]. 
Negative factor (Nef) protein is an HIV regulatory 
protein with an important role in cell apoptosis 
and enhancement of viral infectivity[50]. Nef blocks 
the ATP-binding cassette transporter A1 (ABCA1) 
pathway, leading to impaired cholesterol efflux from 
HIV infected macrophages to HDL particles[51]. As a 
result, HIV-infected macrophages accumulate lipids 
turning into foam cells, a step that may contribute 
to atherosclerosis formation[51]. Like Gp120 and 
Tat protein, Nef decreases endothelium-dependent 
vasorelaxation in porcine pulmonary arteries and 
reduces eNOS expression in both porcine pulmonary 
artery and human pulmonary artery endothelial 
cells[52]. In the same model Nef increased the levels of 
reactive oxygen species (ROS)[52], with an attendant 
decrease in NO bioavailability[53]. In endothelial 
cells, Nef can induce monocyte chemoattractant 
protein-1 (MCP-1) expression and apoptosis through 
NF-kB signaling and ROS-dependent mechanisms, 
respectively[54]. 
In addition to the humoral effects described above, 
cellular immune activation may play a role in the 
increased incidence of CVD in infected patients[35]. 
Monocytes are readily infected by HIV[55]; they adhere 
to the endothelial surface and eventually penetrate 
in the subendothelial space and intima. Monocytes, 
especially intermediate monocytes expressing CD14++ 
and CD16+, are prone to a greater pro-inflammatory 
activity once infected with HIV[56]. Furthermore, Hearps et 
al[57] showed that infected monocytes and macrophages 
of HIV+ patients have a reduced phagocytic activity 
and demonstrate telomere shortening a marker of 
premature ageing. High levels of monocyte activation 
Shahbaz S et al . Cardiovascular disease in HIV
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later the same investigators showed that cumulative 
exposure to some of the protease inhibitors (Indinavir, 
Lopinavir-Ritonavir) was associated with an increased 
risk of myocardial infarction (relative rate per year, 
1.12 and 1.13, respectively) after adjustment for the 
impact of these drugs on lipid metabolism[77]. This was 
the first report that suggested that HAART might be 
responsible for an increased incidence of cardiovascular 
events independent of their lipid effects. The case of 
Abacavir remains paradigmatic in this setting. Several 
observational cohorts and a few randomized clinical 
trials reported an association between current, but 
not cumulative exposure of Abacavir and myocardial 
infarction. Abacavir, as a guanosine analogue, inhibits 
soluble guanylyl cyclase leading to enhanced platelet 
adhesion and, ultimately, to increased risk of myocardial 
infarction[78]. 
Numerous other studies implicated Abacavir and 
protease inhibitors in the development of cardiovascular 
events, however none of the reports provided conclusive 
evidence. The adverse effects of these drugs may 
be particularly harmful in patients with pre-existing 
high cardiovascular risk, and they should therefore be 
avoided in those patients.
In spite of early observations reporting an increased 
risk of CVD in patients receiving HAART, particularly 
protease inhibitors, more recent evidence suggests 
a safer cardio-metabolic profile of some categories 
of HAART[20,79]. Current strategies to decrease the 
risk of CVD in HIV infected patients include early 
initiation of HAART regimens known to be associated 
with the fewest metabolic adverse effects and careful 
management of traditional CV risk factors during 
HAART treatment. 
SCREENING ALGORITHMS 
FOR CARDIOVASCULAR RISK 
STRATIFICATION IN HIV 
Cardiovascular risk assessment in HIV infected patients 
has traditionally been based on recommendations 
drafted for the general population. In 2010 Friis-
Møller et al[80] reported on the performance of a new 
model (derived from the D.A.D. cohort) that included 
exposure to HAART along with traditional risk factors. 
Although the new model estimated outcomes more 
accurately than the Framingham Risk Score (FRS) in 
the HIV population, it has not been widely adopted.
A new risk prediction algorithm for the general 
population [atherosclerotic cardiovascular disease 
(ASCVD)] was introduced in 2013 by the American 
College of Cardiology/American Heart Association[81]. In 
preliminary analyses it appeared that the ASCVD might 
overestimate CVD risk in the general population[82]. 
However the situation is probably the opposite in HIV 
disease. In a cohort of 2270 HIV infected patients, 
Regan et al[83] recently reported that the ASCVD algorithm 
classified a larger proportion of HIV patients as high-
of insulin resistance and diabetes mellitus in patients 
co-infected with hepatitis C virus (HCV). The impact of 
the directly active agents used in the therapy of HCV 
to reduce the incidence of diabetes mellitus is currently 
unknown[66,67]. 
(3) Dyslipidemia: The dyslipidemia that develops 
during HAART is characterized by an increase in total 
and LDL cholesterol, and triglycerides levels. The 
effect varies according to the different HAART classes 
and within each class with different drugs. While this 
drug-induced toxicity was very common with the 
older antiretroviral drugs, it has become much less 
problematic with second generation nucleoside reverse 
transcriptase inhibitors (NRTI), (namely Rilpivirine) 
and with integrase inhibitors (Dolutegravir, Elvitegravir 
and Raltegravir). The HIV is a metabolically active 
virus capable to alter reverse cholesterol transport via 
modification of the HDL particles functionality and/or 
impairment of cellular cholesterol efflux. As discussed 
above, in vitro experiments have demonstrated 
that the HIV-related Nef protein can impair cellular 
cholesterol efflux through down-regulation of ABCA1[68,69]. 
ABCA1 plays a crucial role in stimulating cholesterol 
export from macrophages. Recently Lo et al[68] showed 
that, in the acute phase of HIV infection, HAART can 
restore the HDL-mediated cholesterol efflux capacity 
primarily through the suppression of viremia, providing 
additional evidence that prompt HAART initiation can 
potentially reduce atherosclerotic risk. 
(4) Systemic hypertension: Among HIV infected 
patients the prevalence and incidence of systemic 
hypertension ranges from 20%-40% in high-income 
countries[70-72] to 11%-28% in low and middle income 
countries[73,74]. These trends may reflect the distribution 
of risk in the general populations of the same regions 
of the world. As a result, it is currently unclear whether 
hypertension is more prevalent in HIV infected patients 
than the general population. 
Several studies failed to show a correlation between 
blood pressure levels and CD4 cell count and between 
viral load and hypertension. There are sparse and 
conflicting data on the role of antiretroviral therapy 
in the pathogenesis of hypertension[75,76], and the 
association remains inconclusive. 
Impact of antiretroviral therapy on CVD: The first 
cases of myocardial infarction in HIV-infected patients 
receiving protease inhibitor were described in the late 
1990s; since then several epidemiological studies 
have examined the association between HIV infection, 
HAART and the risk of CVD. In 2003 the investigators 
of the D:A:D study (Data Collection on Adverse 
Events of Anti-HIV Drugs) reported for the first time 
an increased incidence of myocardial infarction with 
longer exposure to combination antiretroviral therapy 
[adjusted risk rate per year of exposure, 1.26 (95%CI: 
1.12-1.41); P < 0.001]. Patients with no exposure to 
therapy had a lower incidence of myocardial infarction 
than any of the treated groups[24]. Several years 
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novel marker of activated macrophages (P = 0.04)[93], 
but not with C-reactive protein (P = 0.65) or D-dimer (P 
= 0.08) levels. 
More recently, Tawakol et al[94] performed 18-FDG-
PET imaging in 41 HIV+ patients on stable HAART 
regimen without prior CVD, but with coronary plaques 
on coronary CT angiography. A higher tracer uptake 
was correlated with the presence of low-attenuation 
plaques (P = 0.02) and positive remodeling (P = 0.04), 
both features of plaque instability. 
Despite these encouraging results, no algorithm 
to date has incorporated imaging information in risk 
models for HIV patients. Therefore risk assessment 
remains reliant on the use of traditional risk factors 
despite their demonstrated limitations, although there 
is hope that imaging may add useful information in the 
future (Figure 3).
MANAGEMENT OF HIV INFECTED 
PATIENTS TO PREVENT CVD
In view of the information discussed so far it appears 
true that the CV risk of HIV infected patients is greater 
than that of the general population; a combination 
of higher prevalence of traditional risk factors and 
HIV specific factors likely predispose patients to such 
increased risk. Four questions emerge regarding risk 
reduction management in HIV patients: (1) should HIV 
infected patients be treated more aggressively than the 
general population for traditional risk factors? (2) As a 
corollary of the former, should a lower risk threshold 
be used to initiate treatment? (3) What HAART should 
be chosen to minimize CV risk in HIV? and (4) Finally, 
should therapy for HIV infected patients be guided by 
imaging and/or non-imaging biomarkers? 
To date no study has addressed the impact of 
more aggressive therapy of traditional risk factors in 
HIV patients to reduce the attendant CV risk. While it 
would appear that there is a trend toward a relative 
reduction of CV morbidity and mortality in the past 
10-15 years[95], it is unclear whether this is due to 
greater physicians’ awareness and increased preventive 
efforts in HIV patients or other as yet unknown factors. 
The current recommendations for risk assessment 
and risk reduction in HIV patients mimic those of the 
general population. However, as discussed above, in 
spite of a slightly better performance of newer versus 
older risk assessment algorithms, the majority of 
patients at risk are not identified as high-risk and are 
therefore not receiving potentially life saving therapies. 
The newest algorithm (ASCVD) lowered the threshold 
for identification of high-risk patients to 7.5% from 
20% as recommended in the ATP-Ⅲ guidelines[96], 
but it continues to under perform in HIV patients. 
In fact, despite the greater proportion of patients at 
risk identified by the ASCVD, as many as 40% of 
the patients suffering an acute cardiovascular event 
would not have met the requirement for prescription 
risk compared to the FRS (25% vs 10%). However, 
comparing the 5-year observed-vs-predicted event 
rates, both models underestimated the actual CVD risk 
in HIV. Similarly, Thompson-Paul et al[84] compared 
ASCVD[81], FRS[85], the European algorithm known 
as SCORE[86] and the DAD score[80] to predict events 
in 2392 ambulatory HIV+ patients. After a median 
follow-up of 6.5 years they recorded 204 events; all 
models underestimated the actual risk of events. The 
FRS, ASCVD, and DAD equations showed moderate 
discrimination (C-statistic range, 0.68 to 0.72), while 
SCORE showed poor discrimination (C-statistic = 0.59).
Imaging of subclinical atherosclerosis has been 
suggested as a method to improve risk prediction 
and implementation of preventive therapies in the 
general population with variable success. Zanni et al[87] 
described a disproportion in HIV infected individuals 
between presence of subclinical atherosclerosis and 
statins recommendation. One third of 108 HIV infected 
patients without known CVD who underwent computed 
tomography angiography hosted coronary artery 
plaques with features of high vulnerability. Although 
a larger number of patients would require statins 
according to the new ASCVD algorithm compared 
to the FRS recommendations (26% vs 10%), the 
majority (74%) of HIV infected patients with subclinical 
coronary atherosclerosis did not have an indication to 
receive treatment even with the new algorithm. 
Coronary artery calcium (CAC) has been proven 
to be incremental to risk factors for the prediction of 
events in the general population[88,89], but to date it 
has not been shown to be as useful in HIV infected 
patients. In a metanalysis Hulten et al[90] described 
a similar prevalence of CAC between HIV-positive 
and uninfected patients (OR: 0.95, P = 0.851). In 
the MACS[91], among 615 HIV infected men and 332 
controls, the adjusted odds ratio for CAC was 1.35 
(95%CI: 0.7-2.61). No outcome study has yet been 
published demonstrating the utility of CAC as an 
incremental prognostic factor in HIV.
Inflammation plays a central role in the patho-
physiology of atherosclerosis and 18-fluorede-
oxyglucose positron emission tomography can identify 
activated macrophages infiltrating the arterial wall. 
Subramanian et al[92] compared 27 HIV positive 
patients receiving HAART without prior CVD, with two 
non-HIV control groups: one group was matched for 
age, sex and FRS (non-HIV, FRS-matched controls), 
while the second one was sex-matched but had known 
atherosclerotic CVD (non-HIV, atherosclerotic controls). 
Inflammation in the aortic wall (measured as target to 
background signal ratio, TBR) was similar between HIV 
infected patients and non-HIV atherosclerotic controls 
(2.23; 95%CI: 2.07-2.40 vs 2.13; 95%CI: 2.03-2.23; 
P = 0.29), but was higher than in the non-HIV FRS-
matched controls (2.23; 95%CI: 2.07-2.40 vs 1.89; 
95%CI: 1.80-1.97; P = 0.001). 
In HIV infected patients the aortic TBR was associated 
with the serum concentration of soluble CD163, a 
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(protease inhibitor) was associated with less IMT 
progression than darunavir (integrase inhibitor), but the 
progression was similar for atanazavir and raltegravir 
(first generation integrase inhibitor) despite the better 
lipid profile of patients receiving raltegravir. Hence, it 
would appear that only part of the pro-atherogenic effect 
of HAART may be dependent upon lipid metabolism 
alterations. Additionally, in a recent publication the 
authors reported that various HAART regimen did not 
differ as far as expression of markers of inflammation 
and immune activation, confirming the notion that 
the anti- or pro-atherogenic effects of HAART cannot 
be gauged by their effect on serological biomarkers 
at the current state of research[100]. The lack of effect 
on biomarkers and a not markedly different effect on 
measures of atherosclerosis suggests that despite a 
reduction of viral load with HAART, there are residual 
immunological perturbations and reservoirs of viral 
replication that may induce atherosclerosis progression. 
Timing of HAART initiation has recently received 
renewed interest with the publication of the INSIGHT-
START trial results[101]. In this trial 4685 HIV infected 
patients were randomized to receive HAART (mainly 
based on tenofovir, emtricitabine and efavirenz) with 
a CD4+ cell count > 500/cc (median CD4+ at initiation 
651/cc) or only once the CD4+ cell count dropped 
below 350/cc. The primary end point was a composite 
of death from all causes, and any serious AIDS related 
and non-AIDS related events (mostly cardiovascular). 
After a mean follow-up of 3 years the patient group 
of statins prior to the event according to two recent 
studies[83,97]. Hence, a mere lowering of the threshold 
for initiation of preventive therapies may be insufficient 
to effectively lower risk of events in HIV patients. In 
view of the difficulties highlighted above, a new study 
was launched[98] that aims to show that early statin 
treatment in asymptomatic HIV infected patients will 
delay the development of inflamed atherosclerotic plaques 
and reduce cardiovascular events (death, myocardial 
infarction, angina, stroke and revascularizations).
The choice of HAART and timing of therapy initiation 
likely carry a significant weight in risk reduction, 
as some of these drugs appear to have both direct 
and indirect cardiovascular toxicity while others may 
lower CV risk. Since the initial observation from the 
SMART study[20] reporting a reduced incidence of CV 
events in patients reaching a stable viral suppression, 
newer antiretroviral agents have been introduced with 
improved cardiometabolic toxicity. However, there are 
currently no long-term studies to demonstrate the 
safety and effectiveness of new anti-retroviral agents 
such as integrase inhibitors, although the safety profile 
of drugs such as atanazavir (a protease inhibitor) 
and tenofovir (member of the NRTI family) has been 
established. To address the paucity of prospective 
follow-up data, the D.A.D. registry has been tasked 
with the collection of safety data on drugs with a 
minimum of 30000 person-year follow-up[99]. 
Surrogate markers of atherosclerosis and serol-
ogical biomarkers may provide some insight into 
the effectiveness of a novel therapeutic agent. In a 
preliminary communication, Stein et al[79] reported 
the effect of various antiretroviral combinations on the 
progression of the intima-medial thickness (IMT) of the 
carotid artery bulb in 234 HIV+ patients followed for a 
maximum of 144 mo from randomization. Atanazavir 
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Figure 3  All algorithms currently used to estimate risk of cardiovascular 
disease in the general population underestimate the actual risk of human 
immunodeficiency virus positive patients. Although unproven, it is likely that a 
combination of traditional risk factors, risk linked with some anti-retroviral agents 
and data on subclinical atherosclerosis collected via imaging, may improve risk 
prediction in the future. ASCVD: Atherosclerotic cardiovascular disease; HAART: 
Highly active antiretroviral therapies; HIV: Human immunodeficiency virus. 
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Figure 4  The pathophysiology of human immunodeficiency virus associated 
atherosclerosis is very complex; a high prevalence of traditional risk factors, 
direct effects of the human immunodeficiency virus virion and side effects of 
some the antiretroviral agents, along with yet unknown genetic and epigenetic 
factors predispose these patients to a high incidence of cardiovascular disease. 
The impact of anti-retroviral therapy is particularly difficult to estimate since suppression 
of viral replication may have an anti-atherosclerotic activity (curved arrow with negative 
sign) while side effect of some antiretroviral drugs may promote atherosclerosis (curved 
arrow with positive sign). HAART: Highly active antiretroviral therapies; LDL: Low-
density lipoprotein; VLDL: Very low-density lipoprotein; HIV: Human immunodeficiency 
virus.
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that received early HAART demonstrated a significantly 
reduced event rate (HR: 0.43; CI: 0.30-0.62, P < 0.001) 
compared to the delayed treatment group. These 
results fuelled an intense debate as to the pros- and 
cons of early HAART initiation, an approach that needs 
to be carefully considered in view of the potential side 
effects of some HAART discussed above. 
CONCLUSION
The etio-pathogenesis of CVD in HIV is very complex, 
with contributions from the retrovirus and the attendant 
immunologic perturbations, HAART, highly prevalent 
traditional risk factors and genetics (Figure 4). There-
fore a multifaceted approach will be necessary to 
effectively prevent its development and progression. 
Since atherosclerosis in HIV patients is characterized 
by immune activation in association with highly 
inflamed, non-calcified, potentially vulnerable plaques, 
these may become the targets of choice in future 
clinical trials to test the effectiveness of therapy. 
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